z-logo
open-access-imgOpen Access
Hepatitis C Virus Core Protein Augments Androgen Receptor-Mediated Signaling
Author(s) -
Tatsuo Kanda,
Robert Steele,
Ranjit Ray
Publication year - 2008
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.01300-08
Subject(s) - biology , androgen receptor , cancer research , angiogenesis , signal transduction , carcinogenesis , transcription factor , hepatitis c virus , stat3 , androgen , hepatocellular carcinoma , immunology , microbiology and biotechnology , endocrinology , virus , cancer , gene , genetics , prostate cancer , hormone
Hepatitis C virus (HCV) infection is frequently associated with the development of hepatocellular carcinoma (HCC), which is one of the male-dominant diseases. Androgen signaling in liver may be related to carcinogenesis. In this study, we investigated whether HCV proteins cross talk with the androgen receptor (AR) signaling pathway for promotion of carcinogenesis. We have demonstrated that HCV core protein alone or in context with other HCV proteins enhances AR-mediated transcriptional activity and further augments in the presence of androgen. Subsequent study suggested that HCV core protein activates STAT3, which in turn enhances AR-mediated transcription. This activity was blocked by a pharmacological inhibitor of the Jak/Stat signaling pathway, AG490. Vascular endothelial growth factor (VEGF) is a target gene of AR in liver and plays an important role in angiogenesis. Therefore, we examined whether HCV infection modulates VEGF expression in hepatocytes. Our results demonstrated that HCV enhances VEGF expression and facilitates tube formation in human coronary microvascular endothelial cells in the presence of AR. Together, our results suggest that HCV core protein acts as a positive regulator in AR signaling, providing further insight into oncogenic potential in the development of HCC in HCV-infected individuals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here